


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:780680 CAPLUS Full-text  
 DN 141:296296  
 TI Preparation of peptidyl lactams for treatment of neurological disorders  
 IN Herzog, Keith John; Jacobs, Robert; Kang, Jianxing; Simpson, Thomas  
 Richard; Woods, James M.  
 PA AstraZeneca AB, Swed.  
 SO PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080983	A1	20040923	WO 2004-SE350	20040310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1636196	A1	20060322	EP 2004-719166	20040310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006520396	T	20060907	JP 2006-507955	20040310
	US 2006183732	A1	20060817	US 2005-549271	20050913
PRAI	US 2003-455100P	P	20030314		
	US 2003-459416P	P	20030401		
	WO 2004-SE350	W	20040310		
OS	CASREACT 141:296296; MARPAT 141:296296				
GI					



AB The invention relates to lactams I [R1 is H, (un)substituted alkylaryl, alkylheterocycl, alkyl, cycloalkyl, etc.; R2, R3, R6, R7 are H, (un)substituted aryl, heteroaryl (at least one is aryl/heteroaryl), alkylaryl, alkylheterocycl, alkyl or cycloalkyl; R4 is H, (un)substituted aryl or heteroaryl; R5 is alkyl, (un)substituted phenylalkyl, 1-hydroxyalkyl, hydroxyphenylmethyl, etc.] or their pharmaceutically-acceptable salts for the treatment of neurol. disorders, e.g., Alzheimer's disease, related to amyloid  $\beta$ -protein production. These novel compds. inhibit secretase and thus inhibit the production of amyloid  $\beta$ -protein and prevent the formation of neurol. deposits of amyloid protein. Syntheses of lactams I are described in 12

examples. Thus, (3S,7S)- or (3S,7R)-3-amino-1-methyl-7-phenyl-1,3,4,7-tetrahydro-2H-azepin-2-one were prepared via cyclization reaction and coupled with N-[ (3,5-difluorophenyl)acetyl]-L-alanine to afford N2-[ (3,5-difluorophenyl)acetyl]-N1-[ (3S,7S)- or (3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide.

IT 762289-09-8P 762289-10-1P 762289-18-9P  
762289-19-0P 762289-25-8P 762289-26-9P  
762289-32-7P 762289-33-8P 762289-34-9P  
762289-35-0P 762289-43-0P 762289-44-1P  
762289-49-6P 762289-50-9P 762289-59-8P  
762289-60-1P 762289-68-9P 762289-69-0P  
762289-75-8P 762289-76-9P 762289-86-1P  
762289-87-2P 762289-96-3P 762289-97-4P  
762289-98-5P 762289-99-6P 762290-00-6P  
762290-01-7P 762290-02-8P 762290-03-9P  
762290-04-0P 762290-05-1P 762290-06-2P  
762290-07-3P 762290-08-4P 762290-09-5P  
762290-10-8P 762290-11-9P 762290-12-0P  
762290-13-1P 762290-14-2P 762290-15-3P  
762290-16-4P 762290-17-5P 762290-18-6P  
762290-19-7P 762290-20-0P 762290-21-1P  
762290-22-2P 762290-23-3P 762290-24-4P  
762290-25-5P 762290-26-6P 762290-27-7P  
762290-28-8P 762290-29-9P 762290-30-2P  
762290-31-3P 762290-32-4P 762290-33-5P  
762290-34-6P 762290-35-7P 762290-36-8P  
762290-37-9P 762290-38-0P 762290-39-1P  
762290-40-4P 762290-41-5P 762290-42-6P  
762290-43-7P 762290-44-8P 762290-45-9P  
762290-46-0P 762290-47-1P 762290-48-2P  
762290-49-3P 762290-51-7P 762290-52-6P  
762290-54-0P 762290-55-1P 762290-57-3P  
762290-59-5P 762290-60-8P 762290-62-0P  
762290-64-2P 762290-66-4P 762290-68-6P  
762290-70-0P 762290-72-2P 762290-73-3P  
762290-74-4P 762290-75-5P 762290-76-6P  
762290-77-7P 762290-78-8P 762290-79-9P  
762290-80-2P 762290-81-3P 762290-82-4P  
762290-83-5P 762290-84-6P 762290-85-7P  
762290-86-8P 762290-87-9P 762290-88-0P  
762290-89-1P 762290-90-4P 762290-91-5P  
762290-92-6P 762290-93-7P 762290-94-8P  
762290-95-9P 762290-96-0P 762290-97-1P  
762290-98-2P 762290-99-3P 762291-00-9P  
762291-01-0P 762291-02-1P 762291-03-2P  
762291-04-3P 762291-05-4P 762291-06-5P  
762291-07-6P 762291-08-7P 762291-09-8P  
762291-10-1P 762291-11-2P 762291-12-3P  
762291-13-4P 762291-14-5P 762291-15-6P  
762291-16-7P 762291-17-8P 762291-18-9P  
762291-19-0P 762291-20-3P 762291-21-4P  
762291-22-5P 762291-23-6P 762291-24-7P  
762291-25-8P 762291-26-9P 762291-27-0P  
762291-28-1P 762291-29-2P 762291-30-5P  
762291-31-6P 762291-32-7P 762291-33-8P  
762291-34-9P 762291-35-0P 762291-36-1P  
762291-37-2P 762291-38-3P 762291-39-4P  
762291-40-7P 762291-41-8P 762291-42-9P  
762291-43-0P 762291-44-1P 762291-45-2P  
762291-46-3P 762291-47-4P 762291-48-5P

762291-49-6P 762291-50-9P 762291-51-0P  
 762291-52-1P 762291-53-2P 762291-54-3P  
 762291-55-4P 762291-56-5P 762291-57-6P  
 762291-58-7P 762291-59-8P 762291-60-1P  
 762291-61-2P 762291-62-3P 762291-63-4P  
 762291-64-5P 762291-65-6P 762291-66-7P  
 762291-67-8P 762291-68-9P 762291-69-0P  
 762291-71-4P 762291-72-5P 762291-73-6P  
 762291-74-7P 762291-75-8P 762291-76-9P  
 762291-77-0P 762291-78-1P 762291-79-2P  
 762291-80-5P 762291-81-6P 762291-82-7P  
 762291-83-8P 762291-85-0P 762291-86-1P  
 762291-87-2P 762291-89-4P 762291-90-7P  
 762291-91-8P 762291-92-9P 762291-93-0P  
 762291-94-1P 762291-95-2P 762291-96-3P  
 762291-97-4P 762291-98-5P 762291-99-6P  
 762292-00-2P 762292-01-3P 762292-02-4P  
 762292-03-5P 762292-04-6P 762292-05-7P  
 762292-06-8P 762292-07-9P 762292-08-0P  
 762292-09-1P 762292-10-4P 762292-11-5P  
 762292-12-6P 762292-13-7P 762292-16-0P  
 762292-18-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidyl lactams for treatment of neurol. disorders)

RN 762289-09-8 CAPPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-10-1 CAPPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-18-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-19-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-25-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3R,7S)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-26-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3R,7R)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-32-7 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3S,7S)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-33-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,7R)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-34-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3S,7R)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-35-0 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,7S)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-43-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1-(phenylmethyl)-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-44-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1-(phenylmethyl)-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-49-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-(2-methoxyethyl)-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-50-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-1-(2-methoxyethyl)-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-59-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3S,7S)-1-cyclopentyl-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-60-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,7S)-1-cyclopentyl-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-68-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-(2-methylpropyl)-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-69-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3R,7S)-2,3,4,7-tetrahydro-1-(2-methylpropyl)-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-75-8 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3S,7S)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2,3,4,7-tetrahydro-2-oxo-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-76-9 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,7S)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2,3,4,7-tetrahydro-2-oxo-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-86-1 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3S,7S)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-7-(4-methoxyphenyl)-2-oxo-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-87-2 CAPLUS

CN Benzeneacetamide, N-[(1S)-2-[(3R,7S)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-7-(4-methoxyphenyl)-2-oxo-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-96-3 CAPLUS

CN Pentanamide, N-[(1S)-1-[[[(3S,7S)-1-(cyclopropylmethyl)-2,3,4,7-tetrahydro-7-(4-methoxyphenyl)-2-oxo-1H-azepin-3-yl]amino]carbonyl]-3-methylbutyl]-2-hydroxy-4-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-97-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-98-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762289-99-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-00-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-01-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-02-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-03-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-04-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762290-05-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-

[(3S)-2,3,4,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-,  
( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-06-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-07-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762290-08-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 762290-09-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-10-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-11-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-12-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,4,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-13-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-14-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-15-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-16-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-17-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-18-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-19-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-20-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-21-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-22-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-23-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,4R)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-24-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-25-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-26-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-27-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-28-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-29-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-30-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-31-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-32-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-33-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-34-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4R,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-35-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4R,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-36-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4R,7S)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-37-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R,7R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-38-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R,7R)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762290-39-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-

[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-40-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-41-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-42-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-43-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-44-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-45-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-46-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-47-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-48-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-49-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-51-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-52-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-54-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-55-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-57-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,4,7-tetrahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-59-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-60-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-62-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-64-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 762290-66-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (as) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-68-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4R)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]-, (αR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-70-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-72-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-73-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-74-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4S)-2,3,4,7-tetrahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-75-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-76-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-  
[(3S,4S)-2,3,4,7-tetrahydro-2-oxo-4,6-diphenyl-1H-azepin-3-  
yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-77-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-78-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-79-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-80-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-81-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7S)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-82-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-83-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-84-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-85-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,7R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-86-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,7R)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-87-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,7R)-2,3,6,7-tetrahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-88-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[[3S,6R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-89-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,6R)-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-90-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-α-hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-91-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-α-hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6R)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-92-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6R)-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-93-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6R)-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-94-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,6S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-95-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S,6S)-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-96-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-97-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S,6S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-98-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,6S]-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762290-99-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[[3S,6S]-2,3,6,7-tetrahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-00-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[[3S]-2,3,6,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-01-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-02-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-03-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-04-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-05-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-06-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-07-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-08-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-α-hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-09-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-α-hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-10-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-11-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro- $\alpha$ -hydroxy-N-[(1S)-1-methyl-2-oxo-2-[(3S)-2,3,6,7-tetrahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-12-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-13-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-14-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-15-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-16-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7R)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-17-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-18-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-19-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-20-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-21-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,7S)-hexahydro-2-oxo-7-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-22-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6R)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-23-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6R)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-24-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6R)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-25-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6R)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-26-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6R)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-27-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-28-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-29-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-30-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-1-methyl-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-31-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy-,  
(αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-32-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,6S)-hexahydro-2-oxo-6-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy-,  
(αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-33-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-34-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-35-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-36-1 CAPLUS


CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-37-2 CAPLUS  
 CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-,  
 ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-38-3 CAPLUS  
 CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-,  
 ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762291-39-4 CAPLUS  
 CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-40-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-41-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-42-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-1-methyl-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-43-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-44-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S)-hexahydro-2-oxo-4-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-45-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-46-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-47-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-48-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-1-methyl-2-

oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-49-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-50-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-51-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-52-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-53-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-1-methyl-2-

oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-54-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-55-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-56-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,7S)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-57-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-58-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-2-oxo-4,7-

diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-59-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-60-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-1-methyl-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-61-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-62-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,7R)-hexahydro-2-oxo-4,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-63-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-64-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-65-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-66-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-67-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-68-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6S)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-69-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-71-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4S,6S)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-72-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[[[(3S,4S,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-73-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[[[(3S,4S,6S)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-74-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1*S*)-2-[(*3S,4S,6S*)-hexahydro-2-oxo-4,6-diphenyl-1*H*-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-,  
( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-75-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1*S*)-2-[(*3S,4S,6S*)-hexahydro-2-oxo-4,6-diphenyl-1*H*-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-,  
( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-76-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1*S*)-2-[(*3S,4R,6R*)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1*H*-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-77-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6R)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-78-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6R)-hexahydro-1-methyl-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-α-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 762291-79-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6R)-hexahydro-1-methyl-2-

oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-80-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6R)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-81-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,4R,6R)-hexahydro-2-oxo-4,6-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-82-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-83-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-85-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-86-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-87-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-89-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-90-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-91-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-92-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-93-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[[[(3S,5S,7S)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-94-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[[[(3S,5R,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-95-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[[[(3S,5R,7S)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-96-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7R)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-97-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7R)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-98-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7R)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762291-99-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R,7R)-hexahydro-1-methyl-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-00-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7R)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-01-3 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S,7R)-hexahydro-2-oxo-5,7-diphenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-02-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-03-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-04-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-05-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-06-8 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-07-9 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5S)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]-alpha-hydroxy-, (alphaR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-08-0 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-09-1 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-10-4 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-11-5 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-1-methyl-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-12-6 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-13-7 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-2-[(3S,5R)-hexahydro-2-oxo-5-phenyl-1H-azepin-3-yl]amino]-1-methyl-2-oxoethyl]- $\alpha$ -hydroxy-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-16-0 CAPLUS

CN Pentanamide, 2-hydroxy-4-methyl-N-[(1S)-3-methyl-1-[[[(3S,7S)-2,3,4,7-tetrahydro-1-(2-methoxyethyl)-2-oxo-7-phenyl-1H-azepin-3-yl]amino]carbonyl]butyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 762292-18-2 CAPLUS

CN Benzeneacetamide, 3,5-difluoro-N-[(1S)-1-methyl-2-oxo-2-[[[(3S,7S)-2,3,6,7-tetrahydro-1-methyl-2-oxo-7-phenyl-1H-azepin-3-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 1 OF 1 MARPAT COPYRIGHT 2007 ACS on STN  
 AN 140:339634 MARPAT Full-text  
 TI Preparation of peptidyl lactams for treatment of neurological disorders  
 IN Becker, Christopher; Dembofsky, Bruce; Jacobs, Robert; Kang, James;  
 Ohnmacht, Cyrus; Rosamond, James; Shenvi, Ashokumar Bhikkappa; Simpson,  
 Thomas; Woods, James  
 PA AstraZeneca AB, Swed.  
 SO PCT Int. Appl., 188 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031154	A1	20040415	WO 2003-SE1534	20031002
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003265202	A1	20040423	AU 2003-265202	20031002
	EP 1554250	A1	20050720	EP 2003-799234	20031002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503862	T	20060202	JP 2004-541383	20031002
	US 2006089346	A1	20060427	US 2005-528640	20050322
PRAI	SE 2002-2929		20021003		
	SE 2002-3829		20021219		
	WO 2003-SE1534		20031002		


GI




AB The invention relates to lactams I [X is C, O, NR1, SO2 or S; Ar1 is an (un)substituted 5- or 6-membered aromatic or heterocyclic ring having 0-3 nitrogen, oxygen or sulfur atoms; R1 is H, alk(en)yl, cycloalkyl-, amino-, acyl- or phenylalkyl or cycloalkylalkynyl; R2, R3 are H, alkyl, cycloalkyl, aryl or heteroaryl or R2 and R3 form a fused Ph or cyclohexyl moiety; R4 is H, (un)substituted alkyl, cycloalkyl, heterocyclyl or aryl; R5 is (un)substituted phenylalkyl, 1-hydroxyalkyl, hydroxyphenylmethyl, etc.] or their pharmaceutically-acceptable salts used for the treatment of neurol. disorders, e.g., Alzheimer's disease, related to amyloid  $\beta$  protein production. These compds. inhibit  $\gamma$  secretase and thus inhibit the production of amyloid  $\beta$  protein and prevent the formation of neurol. deposits of amyloid protein. Syntheses of lactams I are described in 117 examples. Thus, cis-3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4-(5R)-one was prepared via cyclization of Me  $\beta$ -[(2-aminophenyl)thio]-N-[(benzyloxy)carbonyl]-2,5-difluorophenylalaninate and underwent coupling with N-[{(3,5-difluorophenyl)acetyl]-L-alanine to afford N2-[(3,5-difluorophenyl)acetyl]-.

N1-[(2R,3R)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide.

MSTR 1



G1 = CH2  
G10 = 32-25 33-23



G11 = Ph  
G18 = 83

8 G19-G20


G19 = alkylene <containing 1-3 C>  
Patent location: claim 1  
Note: or pharmaceutically acceptable salts  
Note: substitution is restricted

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 12; d his; log y

L2 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 12:51:47 ON 19 JUN 2007)

FILE 'REGISTRY' ENTERED AT 12:52:01 ON 19 JUN 2007

L1 STRUCTURE uploaded

L2 QUE L1

L3 17 S L2

L4 229 S L2 FUL

FILE 'CAPLUS' ENTERED AT 12:52:53 ON 19 JUN 2007

L5 1 S L4

FILE 'MARPAT' ENTERED AT 12:54:09 ON 19 JUN 2007

L6 0 S L4

L7 2 S L4 FUL

L8 1 S L7 NOT L5

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	68.18	246.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-1.51

STN INTERNATIONAL LOGOFF AT 12:55:09 ON 19 JUN 2007